ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vertex Pharmaceuticals will pay Parion Sciences $80 million for access to epithelial sodium channel (ENaC) inhibitors for the treatment of cystic fibrosis. The deal includes P-1037, which is currently in a Phase II study. Vertex and Parion are also planning a study combining P-1037 with Vertex’s CF treatments lumacaftor and ivacaftor in people with two copies of the F508del mutation, the most common mutation driving the disease. Vertex says it will also explore the ENaC inhibitors as treatments for other pulmonary diseases.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X